Is GANX or GHRS more undervalued in 2026?

CirclFi compares Gain Therapeutics, Inc. (GANX) and GH Research PLC (GHRS) using 13 institutional-grade valuation models. GANX has a Quality of Company score of 4.3/10 while GHRS scores 4.4/10.

Which is a better buy — GANX or GHRS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GANX and GHRS valuations compare?

GANX at $2.02 and GHRS at $22.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GANX vs GHRS Valuation Comparison 2026 — Intrinsic Value Analysis

GANX

Biotechnology

Gain Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

LOW

Price

$2.02

Last close

Models

7/13

Active

GHRS

Biotechnology

GH Research PLC

Quality

4.4

out of 10

Value Trap

SAFE

Price

$22.38

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	GANX Fair Value	GANX Upside	GHRS Fair Value	GHRS Upside
Bayesian DCF	Intrinsic	$0.75	-63.0%	$3.69	-83.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.47	-76.7%	$1.40	-93.7%
Dynamic NAV	Asset-Based	$0.64	-68.3%	$2.62	-88.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GANX vs GHRS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GANX vs GHRS — Which Stock Is More Undervalued?

GHRS scores higher with a 4.4/10 quality rating vs GANX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Gain Therapeutics, Inc. (GANX) and GH Research PLC (GHRS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GANX currently trades at $2.02 with a QOC of 4.3/10, while GHRS trades at $22.38 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).